The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Volumn 14, Issue 3, 2013, Pages 162-168

  Berry, James D ^a   Miller, Robert ^b   Moore, Dan H ^b   Cudkowicz, Merit E ^a   Van Den Berg, Leonard H ^c   Kerr, Douglas A ^d   Dong, Yingwen ^d   Ingersoll, Evan W ^e   Archibald, Donald ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d BIOGEN   (United States)

^e SAB: Knopp Biosciences LLC   (United States)

Author keywords

ALS function; ALS survival; Amyotrophic lateral sclerosis; Clinical trials; Primary endpoint; Study design

Indexed keywords

CELECOXIB; DEXPRAMIPEXOLE; PLACEBO;

AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; COMBINED ASSESSMENT OF FUNCTION AND SURVIVAL; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL TIME;

ACTIVITIES OF DAILY LIVING; AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; ENDPOINT DETERMINATION; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); RECOVERY OF FUNCTION; SURVIVAL RATE;

EID: 84875744026     PISSN: 21678421     EISSN: 21679223     Source Type: Journal    
DOI: 10.3109/21678421.2012.762930     Document Type: Article

References (25)

1. Moore DH, Katz JS, Miller RG. A review of clinical trial designs in amyotrophic lateral sclerosis. Neurogen Dis Manage. 2011; 1: 481-90.
2. Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehabil Clin N Am. 2008; 19: 495-508.
3. Berry JD, Cudkowicz ME. New considerations in the design of clinical trials for amyotrophic lateral sclerosis. Clin Investig. 2011; 1: 1375-89.
4. Gordon PH, Corcia P, Lacomblez L, Pochigaeva K, Abitbol JL, Cudkowicz M, et al. Defining survival as an outcome measure in amyotrophic lateral sclerosis. Arch Neurol. 2009; 66: 758-61.
5. Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRS-R predicts survival time in an ALS clinic population. Neurology. 2005; 64: 38-43.
6. Bhatt JM, Gordon PH. Current clinical trials in amyotrophic lateral sclerosis. Expert Opin Investig Drugs. 2007; 16: 1197-207.
7. Bensimon G. Survival endpoint: pro. Amyotroph Lateral Scler. 2002;3:S35-6.
8. European Medicines Agency. European Medicines Agency guidelines. [27 August 2012]. Available from: http://www.ema.europa.eu/ema/.
9. Wittkop L, Smith C, Fox Z, Sabin C, Richert L, Aboulker JP, et al. NEAT-WP4. Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field. Clin Trials. 2010; 7: 19-35.
10. Ferreira-González I, Permanyer-Miralda G, Busse JW, Bryant DM, Montori VM, Alonso-Coello P, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007; 60: 651-7.
11. Freemantle N, Calvert M. Weighing the pros and cons for composite outcomes in clinical trials. J Clin Epidemiol. 2007; 60: 658-9.
12. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984; 40: 1079-87.
13. Wong WK, Furst DE, Clements PJ, Streisand JB. Assessing disease progression using a composite endpoint. Stat Methods Med Res. 2007; 16: 31-49.
14. Lim E, Brown A, Helmy A, Mussa S, Altman DG. Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008; 149: 612-7.
15. Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999; 18: 1341-54.
16. Henderson R, Diggle P, Dobson A. Joint modeling of longitudinal measurements and event time data. Biostatistics. 2000; 1: 465-80.
17. Elashoff RM, Li G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Stat Med. 2007; 26: 2813-35.
18. Moye LA, Davis BR, Hawkins CM. Analysis of a clinical trial involving a combined mortality and adherence dependent interval censored endpoint. Stat Med. 1992; 11: 1705-17.
19. Cudkowicz M, Bozik ME, Ingersoll EW, Miller R, Mitsumoto H, Shefner J, et al. The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis. Nat Med. 2011; 17: 1652-6.
20. Rudnicki SA, Berry JD, Ingersoll E, Archibald D, Cudkowicz ME, Kerr DA, et al. Dexpramipexole effects on functional decline and survival in subjects with amyotrophic lateral sclerosis in a phase II study: subgroup analysis of demographic and clinical characteristics. Amyotroph Lateral Scler. 2013; 14:44-51.
21. Archibald D, Ingersoll EW, Mather JL, Schoenfeld D, Kerr D, Dong Y, et al. Statistical modeling to illustrate the contribution and effects of differential mortality and functional change on joint rank test outcomes in ALS. Amyotroph Lateral Scler. 2011; 12: 107.
22. Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006; 60: 22-31.
23. Healy BC, Schoenfeld DA. Comparison of analysis approaches for phase III clinical trials in amyotrophic lateral sclerosis. Muscle Nerve. 2012;46:506-11.
24. Vonesh EF, Greene T, Schluchter MD. Shared parameter models for the joint analysis of longitudinal data and event times. Stat Med. 2006; 25: 143-63.
25. Tseng C-H, Wong WK. Schluchter MD. Analysis of a composite endpoint with longitudinal and time-to-event data. Stat Med. 2011; 30: 1018-27.